Short Interest in Capstone Therapeutics Corp. (NASDAQ:CAPS) Decreases By 74.3%

Capstone Therapeutics Corp. (NASDAQ:CAPS) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totaling 54,947 shares, a drop of 74.3% from the December 15th total of 213,740 shares. Based on an average trading volume of 162,551 shares, the short-interest ratio is presently 0.3 days. Currently, 1.6% of the shares of the company are short sold. Currently, 1.6% of the shares of the company are short sold. Based on an average trading volume of 162,551 shares, the short-interest ratio is presently 0.3 days.

Capstone Therapeutics Trading Down 3.9%

NASDAQ CAPS traded down $0.03 on Tuesday, hitting $0.63. 186,012 shares of the stock were exchanged, compared to its average volume of 150,626. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.35 and a current ratio of 0.95. Capstone Therapeutics has a 52-week low of $0.61 and a 52-week high of $4.18. The firm has a market capitalization of $5.24 million, a P/E ratio of -0.66 and a beta of -1.21. The stock has a fifty day moving average price of $0.84 and a two-hundred day moving average price of $1.15.

Capstone Therapeutics (NASDAQ:CAPS) last released its earnings results on Tuesday, November 18th. The company reported ($0.35) earnings per share (EPS) for the quarter. Capstone Therapeutics had a negative return on equity of 29.50% and a negative net margin of 12.40%.The firm had revenue of $13.65 million during the quarter.

Institutional Trading of Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. World Investment Advisors purchased a new stake in Capstone Therapeutics Corp. (NASDAQ:CAPS) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 29,000 shares of the company’s stock, valued at approximately $38,000. World Investment Advisors owned about 0.40% of Capstone Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 2.55% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Capstone Therapeutics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Capstone Therapeutics currently has a consensus rating of “Sell”.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.